Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2014 • 26,824 citations

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

2008 • 25,031 citations

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

2017 • 14,809 citations

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

2015 • 8,603 citations

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

2015 • 7,844 citations

Survival Analysis Techniques for Censored and Truncated Data

1998 • 3,691 citations

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

2015 • 3,641 citations

A Multiple Testing Procedure for Clinical Trials

1979 • 3,139 citations

Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck

2004 • 2,992 citations

Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer

2004 • 2,842 citations

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients

2009 • 2,820 citations

Interpreting the significance of changes in health-related quality-of-life scores.

1998 • 2,659 citations

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

2016 • 1,512 citations

Survival analysis using sas®: a practical guide

1995 • 1,225 citations

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer

2007 • 778 citations

HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients

2016 • 668 citations

Survival Analysis

1997 • 660 citations

Immunology and Immunotherapy of Head and Neck Cancer

2015 • 599 citations

PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

2012 • 587 citations

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

2015 • 361 citations

Validation of Methods for Oropharyngeal Cancer HPV Status Determination in US Cooperative Group Trials

2012 • 355 citations

Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

2015 • 305 citations

Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer

2015 • 276 citations

PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment

2014 • 213 citations

An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck

2014 • 81 citations

An international phase 3 trial in head and neck cancer: Quality of life and symptom results

2013 • 37 citations